Literature DB >> 12708584

Plasma amino acid levels in children with autism and their families.

Sarah Aldred1, Kieran M Moore, Michael Fitzgerald, Rosemary H Waring.   

Abstract

Plasma amino acid levels were measured in autistic and Asperger syndrome patients, their siblings, and parents. The results were compared with values from age-matched controls. Patients with autism or Asperger syndrome and their siblings and parents all had raised glutamic acid, phenylalanine, asparagine, tyrosine, alanine, and lysine (p < .05) than controls, with reduced plasma glutamine. Other amino acids were at normal levels. These results show that children with autistic spectrum disorders come from a family background of dysregulated amino acid metabolism and provide further evidence for an underlying biochemical basis for the condition.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12708584     DOI: 10.1023/a:1022238706604

Source DB:  PubMed          Journal:  J Autism Dev Disord        ISSN: 0162-3257


  13 in total

1.  Plasma levels of neuroexcitatory amino acids in patients with migraine or tension headache.

Authors:  Z Alam; N Coombes; R H Waring; A C Williams; G B Steventon
Journal:  J Neurol Sci       Date:  1998       Impact factor: 3.181

2.  Spinal cord GLT-1 glutamate transporter and blood glutamic acid alterations in motor neuron degeneration (Mnd) mice.

Authors:  T Mennini; A Bastone; D Crespi; D Comoletti; C Manzoni
Journal:  J Neurol Sci       Date:  1998-04-15       Impact factor: 3.181

3.  Optical detection of synaptically induced glutamate transport in hippocampal slices.

Authors:  S Kojima; T Nakamura; T Nidaira; K Nakamura; N Ooashi; E Ito; K Watase; K Tanaka; K Wada; Y Kudo; H Miyakawa
Journal:  J Neurosci       Date:  1999-04-01       Impact factor: 6.167

Review 4.  Autism: review of neurochemical investigation.

Authors:  E H Cook
Journal:  Synapse       Date:  1990       Impact factor: 2.562

5.  Hippocampal GABA and glutamate transporter immunoreactivity in patients with temporal lobe epilepsy.

Authors:  G W Mathern; D Mendoza; A Lozada; J K Pretorius; Y Dehnes; N C Danbolt; N Nelson; J P Leite; L Chimelli; D E Born; A C Sakamoto; J A Assirati; I Fried; W J Peacock; G A Ojemann; P D Adelson
Journal:  Neurology       Date:  1999-02       Impact factor: 9.910

6.  Determination of cysteinesulfinate, hypotaurine and taurine in physiological samples by reversed-phase high-performance liquid chromatography.

Authors:  L L Hirschberger; J De La Rosa; M H Stipanuk
Journal:  J Chromatogr       Date:  1985-10-11

7.  Regional differences in the effects of glutamate uptake inhibitor L-trans-pyrrolidine-2,4-dicarboxylic acid on extracellular amino acids and dopamine in rat brain: an in vivo microdialysis study.

Authors:  J Semba; M S Wakuta
Journal:  Gen Pharmacol       Date:  1998-09

8.  The expression of the glial glutamate transporter protein EAAT2 in motor neuron disease: an immunohistochemical study.

Authors:  A E Fray; P G Ince; S J Banner; I D Milton; P A Usher; M R Cookson; P J Shaw
Journal:  Eur J Neurosci       Date:  1998-08       Impact factor: 3.386

9.  Dopamine-beta-hydroxylase (DBH) and homovanillic acid (HVA) in autistic children.

Authors:  C Garnier; E Comoy; C Barthelemy; I Leddet; B Garreau; J P Muh; G Lelord
Journal:  J Autism Dev Disord       Date:  1986-03

10.  Serotonin and amino acid content in platelets of autistic children.

Authors:  L H Rolf; F Y Haarmann; K H Grotemeyer; H Kehrer
Journal:  Acta Psychiatr Scand       Date:  1993-05       Impact factor: 6.392

View more
  57 in total

Review 1.  Improving the prediction of response to therapy in autism.

Authors:  Stephen Bent; Robert L Hendren
Journal:  Neurotherapeutics       Date:  2010-07       Impact factor: 7.620

2.  In vivo 1H-magnetic resonance spectroscopy study of the attentional networks in autism.

Authors:  Silvia Bernardi; Evdokia Anagnostou; Jun Shen; Alexander Kolevzon; Joseph D Buxbaum; Eric Hollander; Patrick R Hof; Jin Fan
Journal:  Brain Res       Date:  2010-12-23       Impact factor: 3.252

Review 3.  Medical treatment overview: traditional and novel psycho-pharmacological and complementary and alternative medications.

Authors:  Evdokia Anagnostou; Robin Hansen
Journal:  Curr Opin Pediatr       Date:  2011-12       Impact factor: 2.856

4.  Chronomics of autism and suicide.

Authors:  F Halberg; G Cornélissen; J Panksepp; K Otsuka; D Johnson
Journal:  Biomed Pharmacother       Date:  2005-10       Impact factor: 6.529

5.  Nonvesicular release of glutamate by glial xCT transporters suppresses glutamate receptor clustering in vivo.

Authors:  Hrvoje Augustin; Yael Grosjean; Kaiyun Chen; Qi Sheng; David E Featherstone
Journal:  J Neurosci       Date:  2007-01-03       Impact factor: 6.167

6.  Epigenetic overlap in autism-spectrum neurodevelopmental disorders: MECP2 deficiency causes reduced expression of UBE3A and GABRB3.

Authors:  Rodney C Samaco; Amber Hogart; Janine M LaSalle
Journal:  Hum Mol Genet       Date:  2004-12-22       Impact factor: 6.150

Review 7.  Emerging drugs for the treatment of symptoms associated with autism spectrum disorders.

Authors:  Logan K Wink; Martin H Plawecki; Craig A Erickson; Kimberly A Stigler; Christopher J McDougle
Journal:  Expert Opin Emerg Drugs       Date:  2010-09       Impact factor: 4.191

Review 8.  Early pharmacological treatment of autism: a rationale for developmental treatment.

Authors:  Terrence C Bethea; Linmarie Sikich
Journal:  Biol Psychiatry       Date:  2007-02-15       Impact factor: 13.382

Review 9.  Nutritional status of individuals with autism spectrum disorders: do we know enough?

Authors:  Sobhana Ranjan; Jennifer A Nasser
Journal:  Adv Nutr       Date:  2015-07-15       Impact factor: 8.701

10.  Distinct plasma profile of polar neutral amino acids, leucine, and glutamate in children with Autism Spectrum Disorders.

Authors:  Rabindra Tirouvanziam; Tetyana V Obukhanych; Julie Laval; Pavel A Aronov; Robin Libove; Arpita Goswami Banerjee; Karen J Parker; Ruth O'Hara; Leonard A Herzenberg; Leonore A Herzenberg; Antonio Y Hardan
Journal:  J Autism Dev Disord       Date:  2012-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.